News
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...
StockStory.org on MSN13d
Biogen (NASDAQ:BIIB) Reports Bullish Q2
Biotech company Biogen (NASDAQ:BIIB) in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of ...
NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...
Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...
Wall Street analysts forecast that Biogen Inc. (BIIB) will report quarterly earnings of $3.94 per share in its upcoming release, pointing to a year-over-year decline of 25.4%. It is anticipated ...
Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...
Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...
StockStory.org on MSN15d
Biogen Earnings: What To Look For From BIIB
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues ...
ImmunityBio (IBRX) stock gains as its CAR-NK cell therapy shows promise in an early stage trial, with lymphoma patients ...
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the August 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results